Compagnie Lombard Odier S Cm A Denali Therapeutics Inc. Transaction History

Compagnie Lombard Odier S Cm A

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 Apr 27, 2022	SELL	$29.0 - $47.27 $87,000 - $141,810	-3,000 Closed	0 $0
Q1 2021 Apr 23, 2021	SELL	$53.8 - $81.53 $53,800 - $81,530	-1,000 Reduced 25.0%	3,000 $171,000
Q4 2020 Feb 09, 2021	BUY	$36.89 - $93.56 $147,560 - $374,240	4,000 New	4,000 $335,000

237

111M

80K

36.8K

Ticker DNLI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 134,174,000
Market Cap $1.98B
Description
Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatm...

Get notified when there are updates to the investment portfolio of Compagnie Lombard Odier S Cm A, based on Form 13F filings with the SEC.

Stay updated on Compagnie Lombard Odier S Cm A with notifications on news.